Compare LEN & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEN | TEVA |
|---|---|---|
| Founded | 1954 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | LEN | TEVA |
|---|---|---|
| Price | $116.40 | $33.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $111.46 | $37.25 |
| AVG Volume (30 Days) | 2.4M | ★ 9.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.82 | $2.97 |
| P/E Ratio | ★ $15.20 | $28.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $98.42 | $12.47 |
| 52 Week High | $144.24 | $37.35 |
| Indicator | LEN | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 52.26 |
| Support Level | $109.10 | $30.70 |
| Resistance Level | $118.16 | $35.32 |
| Average True Range (ATR) | 3.96 | 0.91 |
| MACD | -0.06 | -0.22 |
| Stochastic Oscillator | 49.77 | 12.16 |
Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.